Text Size

The Effect of Exenatide on Weight and Hunger in Obese, Healthy Women

This study has been completed.
Sponsor:
Collaborators:
Amylin Pharmaceuticals, LLC.
Eli Lilly and Company
Information provided by (Responsible Party):
Eleftheria Maratos-Flier, Beth Israel Deaconess Medical Center
ClinicalTrials.gov Identifier:
NCT00456885
First received: April 4, 2007
Last updated: February 24, 2012
Last verified: February 2012
History of Changes
  Purpose

This study will look at the effect of exenatide, a drug which has been approved for the treatment of type 2 diabetes, on body weight, appetite and energy expenditure among moderately obese women without diabetes.

The study is 35 weeks long and includes 19 outpatient visits. Participants will receive exenatide for 16 weeks and placebo for 16 weeks with a 3 week rest period in between. Neither participants nor investigators will know whether exenatide or placebo is being administered. Participants will be started randomly on either exenatide or placebo.

Our hypothesis is that treatment with exenatide will curb appetite and lead to weight loss and may lead to changes in energy expenditure.


Condition Intervention Phase
Obesity
Impaired Glucose Tolerance
 Drug: exenatide
 Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: The Effect of Exenatide on Body Weight, Energy Expenditure and Hunger in Obese Women Without Diabetes Mellitus

Resource links provided by NLM:

Drug Information available for: Exenatide
U.S. FDA Resources

Further study details as provided by Beth Israel Deaconess Medical Center:

Primary Outcome Measures:
  • weight loss [ Time Frame: 37 Weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Changes in resting and total energy expenditure [ Time Frame: 37 Weeks ] [ Designated as safety issue: No ]
  • Changes in sleep patterns [ Time Frame: 37 Weeks ] [ Designated as safety issue: No ]
  • Changes in hunger, satiety and nausea [ Time Frame: 37 Weeks ] [ Designated as safety issue: No ]
  • Changes in food intake [ Time Frame: 37 Weeks ] [ Designated as safety issue: No ]
  • Changes in metabolic parameters [ Time Frame: 37 Weeks ] [ Designated as safety issue: No ]
  • Changes in body composition [ Time Frame: 37 Weeks ] [ Designated as safety issue: No ]
  • Changes in inflammatory markers [ Time Frame: 37 Weeks ] [ Designated as safety issue: No ]

Enrollment: 42
Study Start Date: April 2007
Study Completion Date: September 2010
Primary Completion Date: September 2010 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: exenatide
    5 microgram twice a day for two week and then 10 mcg for remaining 15 weeks
    Other Name: Byetta
Detailed Description:

This study will examine the effect of exenatide on body weight, energy expenditure, satiety, sleep, and metabolic parameters in healthy, moderately obese women (BMI 28-35 kg/m2). We will look at 2 populations of women, one with normal glucose metabolism and one with impaired glucose homeostasis (IGH)--either impaired fasting glucose (IFG, fasting glucose 101-125 mg/dL) or impaired glucose tolerance (IGT, glucose 140-199 mg/dL 2h after a 75g oral glucose load). This is a randomized, double blind, crossover study with two 16-week treatment periods separated by a 3-week washout period. There are 19 study visits over 35 weeks.

The goals of this study are 1) to examine the effect of exenatide on body weight and dysglycemia in populations in which this medication has not been studied, namely obese women with and without IGH and 2) to investigate possible mechanisms of weight loss through measurements of energy expenditure, hunger, satiety, nausea, and sleep.

The primary outcome of this study is weight loss. We will calculate absolute and relative change in body weight from baseline to week 16 (the first treatment period) and from week 19 to week 35 (the second treatment period). Body weight will be measured at every study visit which will also allow us to assess the absolute and relative change from baseline throughout the entire study.

  Eligibility

Ages Eligible for Study:   25 Years to 60 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Females aged 25-60
  2. BMI 28-35 kg/m2
  3. No known diagnosis of diabetes
  4. No known diagnosis of coronary heart disease
  5. Self-described sedentary lifestyle with minimal regular cardiovascular exercise (no more than 1 hour per week)
  6. Stable weight (variation < 3 kg within 6 months of screening visit)
  7. Ability to give informed consent
  8. Ability to follow verbal and written instructions
  9. Use of medically approved form of contraception (monophasic oral contraception, intra uterine device, surgical sterilization or 2 combined barrier methods)
  10. Nonsmoker (tobacco, marijuana)
  11. Outpatient visits every 2 weeks throughout the study period are required. While most of these visits are short (15 minutes)ability to commute to the performance site in Boston, on a regular basis, is necessary.

Exclusion Criteria:

  1. Type 1 or type 2 diabetes mellitus diagnosed according to American Diabetes Association criteria
  2. Coronary heart disease (history of myocardial infarction or unstable angina pectoris)
  3. Uncontrolled hypertension hypertension (BP > 150/90 mmHg on or off antihypertensive medication)
  4. Uncontrolled dyslipidemia (LDL > 200 or TG > 400 on or off lipid lowering medication)
  5. Tobacco, marijuana or intravenous drug use
  6. Shift workers (night shift or alternating day/night shifts)
  7. Recent weight loss (> 3 kg within 4 months of the screening visit)
  8. Gastroparesis
  9. Inflammatory bowel disease
  10. Malignancy treated with chemotherapy within the past 3 years
  11. History of pancreatitis
  12. Depression requiring hospitalization or diagnosis of psychosis
  13. Renal insufficiency (creatinine clearance < 50 ml/min)
  14. Transaminases > 2x above the normal range
  15. Pregnancy within 6 months of the screening visit
  16. Breastfeeding
  17. Failure to use medically approved contraceptive methods
  18. History of an eating disorder (anorexia, bulimia or laxative abuse)
  19. History of surgery for the treatment of obesity (gastric banding, gastric bypass, gastric stapling)
  20. New diagnosis of hypo or hyperthyroidism within 1 year of screening visit
  21. Previous participation in a clinical study with exenatide
  22. Presence or history of allergic reaction to multiple drugs
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00456885

Locations
United States, Massachusetts
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States, 02215
Sponsors and Collaborators
Beth Israel Deaconess Medical Center
Amylin Pharmaceuticals, LLC.
Eli Lilly and Company
Investigators
Principal Investigator: Eleftheria Maratos-Flier, MD Beth Israel Deaconess Medical Center
  More Information

No publications provided

Responsible Party: Eleftheria Maratos-Flier, Professor of Medicine, Beth Israel Deaconess Medical Center
ClinicalTrials.gov Identifier: NCT00456885     History of Changes
Other Study ID Numbers: 2006-p-000361, BFA912
Study First Received: April 4, 2007
Last Updated: February 24, 2012
Health Authority: United States: Institutional Review Board

Keywords provided by Beth Israel Deaconess Medical Center:
obesity
double blind
placebo controlled
 weight loss
appetite
energy expenditure

Additional relevant MeSH terms:
Obesity
Glucose Intolerance
Overnutrition
Nutrition Disorders
Overweight
Body Weight
Signs and Symptoms
 Hyperglycemia
Glucose Metabolism Disorders
Metabolic Diseases
Exenatide
Hypoglycemic Agents
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on June 17, 2013